Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?

Paul Gougis; Charlotte Fenioux; Christian Funck-Brentano; Marianne Veyri; Joseph Gligorov; Caroline Solas; Jean-Philippe Spano

doi:10.1016/j.ejca.2020.05.027

Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?

Eur J Cancer. 2020 Sep:136:1-3. doi: 10.1016/j.ejca.2020.05.027. Epub 2020 Jun 10.

Authors

Paul Gougis¹, Charlotte Fenioux², Christian Funck-Brentano³, Marianne Veyri⁴, Joseph Gligorov⁵, Caroline Solas⁶, Jean-Philippe Spano⁴

Affiliations

¹ Sorbonne Université, INSERM, CIC-1901 Paris-Est, CLIP(2) Galilée, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Pharmacology, F-75013 Paris, France; Sorbonne Université, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Oncology, F-75013 Paris, France; Institut Universitaire de Cancérologie. AP-HP Sorbonne Université, Paris, France. Electronic address: paul.gougis@aphp.fr.
² Sorbonne Université, INSERM, CIC-1901 Paris-Est, CLIP(2) Galilée, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Pharmacology, F-75013 Paris, France; Institut Universitaire de Cancérologie. AP-HP Sorbonne Université, Paris, France.
³ Sorbonne Université, INSERM, CIC-1901 Paris-Est, CLIP(2) Galilée, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Pharmacology, F-75013 Paris, France.
⁴ Sorbonne Université, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Oncology, F-75013 Paris, France; Institut Universitaire de Cancérologie. AP-HP Sorbonne Université, Paris, France; INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, équipe Theravir, France.
⁵ Institut Universitaire de Cancérologie. AP-HP Sorbonne Université, Paris, France; Sorbonne Université, INSERM U-938, CLIP(2) Galilée, Assistance-Publique - Hôpitaux de Paris, Tenon Hospital, Medical Oncology Department, Paris, France.
⁶ Aix Marseille Univ, APHM, INSERM 1207, IRD 190, UVE, Hôpital La Timone, Laboratoire de Pharmacocinétique et Toxicologie, F-13005 Marseille, France.

Abstract

•
We summarised immunosuppressing anticancer drugs which could worsen COVID 19 infections.
•
Other drugs were studied for drug-drug interactions with antiviral medicines.
•
A ready-to-use table synthesised these interactions between antiviral and anticancer drugs.

Keywords: Anticancer drugs; Antiviral interactions; COVID-19; Drug interactions; Drug-induced long QT syndrome.

Publication types

Letter

MeSH terms

Amides / adverse effects
Amides / metabolism
Antibodies, Monoclonal, Humanized / adverse effects
Antineoplastic Agents / adverse effects*
Antineoplastic Agents, Hormonal / adverse effects
Antineoplastic Agents, Immunological / adverse effects
Antiviral Agents / adverse effects*
Betacoronavirus
COVID-19
COVID-19 Drug Treatment
Chemical and Drug Induced Liver Injury / etiology
Coronavirus Infections / complications
Coronavirus Infections / drug therapy*
Cytochrome P-450 Enzyme System / metabolism
Drug Combinations
Drug Interactions
Histone Deacetylase Inhibitors / adverse effects
Humans
Hydroxychloroquine / adverse effects
Immunosuppression Therapy / adverse effects
Kidney Diseases / chemically induced
Long QT Syndrome / chemically induced
Lopinavir / adverse effects
Neoplasms / complications
Neoplasms / drug therapy*
Pandemics
Pneumonia, Viral / complications
Pneumonia, Viral / drug therapy*
Poly(ADP-ribose) Polymerase Inhibitors / adverse effects
Proteasome Inhibitors / adverse effects
Protein Kinase Inhibitors / adverse effects
Pyrazines / adverse effects
Pyrazines / metabolism
Ritonavir / adverse effects
SARS-CoV-2

Substances

Amides
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Antineoplastic Agents, Immunological
Antiviral Agents
Drug Combinations
Histone Deacetylase Inhibitors
Poly(ADP-ribose) Polymerase Inhibitors
Proteasome Inhibitors
Protein Kinase Inhibitors
Pyrazines
lopinavir-ritonavir drug combination
Lopinavir
Hydroxychloroquine
Cytochrome P-450 Enzyme System
favipiravir
tocilizumab
Ritonavir